RS
CYTK icon

R Squared’s Cytokinetics CYTK Stock Holding History

R Squared’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
+2,350
New +$169K 0.11% 347
2025
Q1 		– Sell
-2,830
Closed -$133K – 600
2024
Q4 		$133K Buy
+2,830
New +$147K 0.13% 197

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

R Squared's CYTK Position: Q2 2026 in Review

R Squared opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,350 shares worth $200K. The stake represents 0.11% of the portfolio and ranks #347 among its holdings. This is a return to the name: R Squared previously reported a position in CYTK as recently as Q4 2024.

R Squared first reported a position in CYTK in Q4 2024 and has held it in 2 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • R Squared held 2,350 shares of Cytokinetics worth $200K as of Q2 2026.
  • Cytokinetics was a new R Squared position in Q2 2026.
  • Cytokinetics made up 0.11% of R Squared's portfolio in Q2 2026, its #347 holding.
  • R Squared first reported a position in Cytokinetics in Q4 2024 and has held it in 2 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.